Birdie33 schreef op 2 november 2017 08:40:
Zacks Investment Research upgraded shares of Pharming Group (NASDAQ:PHGUF) from a hold rating to a buy rating in a research report report published on Friday. Zacks Investment Research currently has $1.00 price objective on the biotechnology company’s stock.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Goed nieuws